web analytics
15.8 C
Munich
Saturday, July 24, 2021

Comeback Time for Enzolytics Inc (OTCMKTS: ENZC)

Microcapdaily has been reporting on the wild rise of Enzolytics Inc (OTCMKTS: ENZC) which ran to highs of $0.124 as the Company consummated its merger with BioClonetics, a Company that has created a cell line that produces a fully human monoclonal antibody, the Clone 3 antibody, that binds to and neutralizes the HIV virus. Through a merger of biotech companies, Enzolytics now advances two separate but complementary therapy platforms for treating infectious diseases, targeting HIV and the CoronaVirus. The Company is extending its lab capabilities on the Texas A&M University campus at the Institute for Pre-clinical Studies, where it will be producing both addition monoclonal antibodies against HIV and the against the CoronaVirus. This expansion allows Enzolytics to complete the production of monoclonal antibodies against both the HIV virus and the coronavirus and collaborate with the biopharma experts on the campus.

Enzolytics has attracted a major league level management team behind it which speaks of big things on the horizon. They recently appointed Ronald Moss, M.D., to the Medical Advisory Board; an executive with numerous biotech’s over the past 25 years who has extensive clinical and regulatory management expertise in guiding programs through Phase I, II, and III clinical trials, including IND and NDA. Enzolytics’s CSO, Henry Zhabilov is the inventor of several U.S. patents related to the immunotherapy of HIV and cancer and an immune enhancer based on the company’s IPF platform.

Enzolytics Inc (OTCMKTS: ENZC) is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Immunotech is committed to creating drugs for the better health of mankind. Enzolytics is a 49% shareholder of IMMB BG. Enzolytics’ flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.The Company is merging with BioClonetics Immunotherapeutics, Inc; a Dallas Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology for producing fully human monoclonal antibodies may be used to produce therapeutics treatments for named infectious diseases including the Coronavirus.

The Company is led by CEO and majority shareholder Charles S. Cotropia, a well-known intellectual property attorney who has litigated over 200 patents in his career and served as lead counsel in several landmark patent disputes litigated in Federal Courts and the US Patent and Trademark Office. Mr. Cotropia founded BioCLonetics along with his brother Dr. Joseph Cotropia, MD, who pioneered BioCLonetics proprietary method for creating human cell lines that produce human antibodies directed against many infectious diseases. One cell (designated as CLONE 3) has been demonstrated in multiple tests and 5 Independent studies to neutralize the HIV virus in 98% of all known varieties world-wide.

To Find out the inside Scoop on ENZC Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

ENZCEarlier this month ENZC announced the filing of a provisional patent with the U.S. Patent Office on December 9, 2020 for a treatment of Multiple Sclerosis developed by Harry Zhabilov, titled NUCLEAR PROTEINS ISOLATED FROM MAMALIAN SPINAL CORD (SCNP) IMMUNE FACTOR, Ser. No. 62/123341. The Company received confirmation of filing from the U.S. Patent Office today.

The patent covers pharmaceutical compositions developed by the inventor Harry Zhabilov, CSO of the Company, which are suitable for the treatment of several disorders including certain immune disorders, congenital defects involving primary T cell deficiency, viral infections, HIV and immunosuppression following cancer treatment. The new proprietary technology will be developed by ENZC in combination with its ongoing development of monoclonal antibodies against both HIV and the CoronaVirus in our recently established laboratory facility at Texas A & M University’s Institute for Preclinical Studies.

On December 14 ENZC announced it has engaged SAMM SOLUTIONS, INC. (DBA BTS Research), through a Master Service Agreement to conduct a toxicity study on the Company’s Flagship compound ITV-1. The Company has previously tested the compound in successful Clinical Trials in Bulgaria, but FDA regulations require separate Toxicity tests before an Investigational New Drug process may begin in the United States. BTS Research has performed numerous studies for small and large biotech companies since 2001. Enzolytics is planning to schedule the toxicity study in the first quarter of 2021. The MSA provides for ongoing services and studies Enzolytics seeks to conduct and that BTS provides.

ENZC management added: “Dr. Moss has been instrumental in guiding Enzolytics in our current efforts to bring our product to the US Market. This is a big step for our organization, and we hope to be able to use most if not all of the information from our already successful Clinical Trials in Bulgaria to speed our attempt to meet the requirements in the US for approval. With the recent filing of a provisional patent for treatment of MS and our ongoing work on testing monoclonal antibodies (mAbs), we feel that the combined companies’ potential is just beginning to be realized, in addition to all the hard work going into our research and development efforts, we expect our OTC filings to be completed soon.

For more on ENZC Subscribe Right Now!

Microcapdaily has been reporting on the wild rise of ENZC which ran to highs of $0.124 since September 16 long before ENZC reached a penny. The big move up came as Enzolytics consummated its merger with BioClonetics, a Company that has created a cell line that produces a fully human monoclonal antibody, the Clone 3 antibody, that binds to and neutralizes the HIV virus. Through a merger of biotech companies, Enzolytics now advances two separate but complementary therapy platforms for treating infectious diseases, targeting HIV and the CoronaVirus. The Company is extending its lab capabilities on the Texas A&M University campus at the Institute for Pre-clinical Studies, where it will be producing both addition monoclonal antibodies against HIV and the against the CoronaVirus. This expansion allows Enzolytics to complete the production of monoclonal antibodies against both the HIV virus and the coronavirus and collaborate with the biopharma experts on the campus. Enzolytics has attracted a major league level management team behind it which speaks of big things on the horizon. They recently appointed Ronald Moss, M.D., to the Medical Advisory Board; an executive with numerous biotech’s over the past 25 years who has extensive clinical and regulatory management expertise in guiding programs through Phase I, II, and III clinical trials, including IND and NDA. Enzolytics’s CSO, Henry Zhabilov is the inventor of several U.S. patents related to the immunotherapy of HIV and cancer and an immune enhancer based on the company’s IPF platform. We will be updating on ENZC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ENZC.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in ENZC either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.